Synthesis and evaluation of 17α-20E-21-(4-substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols as probes for the estrogen receptor α hormone binding domain

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 2865-2876

  Hanson, Robert N ^a   Lee, Choon Young ^a   Friel, Carolyn J ^a   Dilis, Robert ^a   Hughes, Alun ^b   DeSombre, Eugene R ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA 21 (4 ACETYLPHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL; 17ALPHA 21 PHENYL 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17BETA DIOL DERIVATIVE; ACOLBIFENE; ARZOXIFENE; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR ALPHA; IDOXIFENE; LASOFOXIFENE; NNC 450781; PALLADIUM; PIPENDOXIFENE; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG; 21 (4 ACETYLPHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 DIOL; 21-(4-ACETYLPHENYL)-19-NORPREGNA-1,3,5(10),20-TETRAENE-3,17-DIOL; ESTROGEN RECEPTOR; LIGAND; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DRUG SYNTHESIS; MOLECULAR DYNAMICS; MOLECULAR MODEL; PROTEIN DOMAIN; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING COMPETITION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; HAMSTER; METABOLISM; PROTEIN TERTIARY STRUCTURE; RADIOASSAY; SYNTHESIS;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; LIGANDS; MODELS, MOLECULAR; NORPREGNATRIENES; PROTEIN STRUCTURE, TERTIARY; RADIOLIGAND ASSAY; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038798622     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205806     Document Type: Article

References (58)

1. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. Cancer Statistics 2002. Ca - Cancer J. Clin. 2002, 52, 23-47.
2. Gradishar, W. J.; Jordan, V. C. Hormonal therapy for breast cancer. An update. Hematol. Oncol. Clin. North Am. 1999, 13, 435-455.
3. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstromm, O.; Ohman, L.; Greene, G. L.; Gustafsson, J.-A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (London) 1997, 389, 753-758.
4. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
5. Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. Crystallographic comparison of the estrogen and progesterone receptors ligand binding domains. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5998-6003.
6. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E.; Bona, T.; Thorsell, A.-M.; Engstrom, O.; Ljunggren, J.; Gustafsson, J.-A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and full antagonist. EMBO J. 1999, 18, 4608-4618.
7. Levenson, A. S.; MacGregor-Schafer, J. I.; Bentrm, D. J.; Pease, K. M.; Jordan, V. C. Control of the estrogen-like action of tamoxifen - estrogen receptor complex by the surface amino acid at position 351. J. Steroid Biochem. Mol. Biol. 2001, 76, 61-70.
8. Jordan, V. C.; MacGregor-Schafer, J.; Levenson, A. S.; Liu, H.; Pease, K. M.; Simons, L. A.; Zapf, J. W. Molecular classification of estrogens. Cancer Res. 2001, 61, 6619-6623.
9. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E. A structural biologist's view of the oestrogen receptor. J. Steroid Biochem. Mol. Biol. 2000, 74, 261-268.
10. Katzenellenbogen, B. S.; Choi, I.; Delage-Mourroux, R.; Ediger, T. R.; Martini, P. G. V.; Montano, M.; Sun, J.; Weis, K.; Katzenellenbogen, J. A. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. 2000, 74, 279-285.
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351, 1451-1467.
12. Johnston, S. R. D.; Riddle, S.; Haynes, B. P.; Hern, R. A.; Smith, I. E.; Jarman, M.; Dowsett, M. The novel anti-estrogen iodoxifene inhibits the growth of human cancer xenografts and reduces the frequency of acquired anti-estrogen resistance. Br. J. Cancer 1997, 75, 804-809.
13. Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Falcone, J. F.; Clemens, J. A. Anti-estrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-2-yl][4-[2-(1-piperidinyl) ethoxy]phenyl]methanone hydrochloride LY 156758, a remarkably effective estrogen antagonist with only minimal intrinsic activity. J. Med. Chem. 1984, 27, 1057-1066.
14. Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. L.; Pell, T. R.; Bryant, H. U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy]phenoxy]2-(4-hydroxyphenyl)] benzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997, 40, 1407-1416.
15. LaBrie, F.; LaBrie, C.; Belanger, A.; Simard, J.; Gauthier, S.; Luu-The, V.; Merand, Y.; Giguere, V.; Candas, B.; Luo, S.; Martel, C.; Singh, S. M.; Fournier, M.; Coquet, A.; Richard, V.; Charbonneau, R.; Charpanet, G.; Tremblay, A.; Cusan, L.; Villeux, R. EM-652 (SCH 57068), a third generation SERM acting as a pure anti-estrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol. 1999, 69, 51-84.
16. Greenberger, L. M.; Annablr, T.; Collins, K. I.; Komm, B. S.; Lyttle, C. R.; Miller, C. P.; Satyaswaroop, P. G.; Zhang, Y.; Frost, P. A new anti-estrogen, 2-(4-hydroxy-phenyl)-3-methyl-l-[4-(2-piperidin-2-yl-ethoxy-)benzyl]-1H- indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotrophic effects in mice and rats. Clin. Cancer Res. 2001, 7, 3166-3177.
17. Meegan, M. J.; Hughes, R. B.; Lloyd, D. G.; Williams, D. C.; Zisterer, D. M. Ethyl side-chain modifications in novel flexible anti-estrogens - design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line. Anti-Cancer Drug Des. 2001, 16, 57-69.
18. Weatherman, R. V.; Carroll, D. C.; Scanlan, T. S. Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site. Bioorg. Med. Chem. Lett. 2001, 11, 3129-3131.
19. Rosati, R. L.; Da Silva, J.; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP 336156, a diaryltetrahydronaphthalene. J. Med. Chem. 1998, 41, 2928-2931.
20. Bury, P. S.; Christiansen, L. B.; Jacobsen, P.; Jorgensen, A. S.; Kanstrup, A.; Naerum, L.; Bain, S.; Fledelius, C.; Gissel, B.; Hansen, B. S.; Korsgaard, N.; Thorpe, S. M.; Wasserman, K. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg. Med. Chem. 2002, 10, 125-145.
21. Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem. Biol. 1999, 6, 205-219.
22. Stauffer, S. R.; Katzenellenbogen, J. A. Solid-phase synthesis of tetra-substituted pyrazoles, novel ligands for the estrogen receptor. J. Comb. Chem.2000, 2, 318-329.
23. Stauffer, S. R.; Huang, Y.; Coletta, C. J.; Tedesco, R.; Katzenellenbogen, J. A. Estrogen pyrazoles: Defining the pyrazole core structure and the orientation of substituents in the ligand binding pocket of the estrogen receptor. Bioorg. Med. Chem. 2001, 9, 141-150.
24. Mortensen, D. S.; Rodriguez, A. L.; Carlson, K. E.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Synthesis and biological evaluation of a novel series of furans: Ligands selective for the estrogen receptor-α. J. Med. Chem. 2001, 44, 3838-3848.
25. Napolitano, E.; Fiaschi, R.; Hanson, R. N. Structure-activity relationships of estrogenic ligands. Synthesis and evaluation of (17α,20E/Z)-21-halogenated-19-norpregna-1,3,5(10),20-tetraene-3, 17β-diols. J. Med. Chem. 1991, 34, 2754-2759.
26. Napolitano, E.; Fiaschi, R.; Herman, L. W.; Hanson, R. N. Synthesis and estrogen receptor binding of (17α,20E)- and (17α,20Z)-21-phenylthio-and phenylseleno-19-norpregna-1,3,5(10),-20-tetraene-3,17β-diols. Steroids 1996, 61, 384-387.
27. Hanson, R. N.; Herman, L. W.; Fiaschi, R.; Napolitano, E. Stereochemical probes for the estrogen receptor: Synthesis and receptor binding of (17α,20E/Z)-21-phenyl-19-norpregna-1,3,5-(10), 20-tetraene-3, 17β-diols. Steroids 1996, 61, 718-722.
28. Hanson, R. N.; Napolitano, E.; Fiaschi, R. Novel high affinity steroidal estrogenic ligands: Synthesis and receptor binding of 11β-vinyl-17α-E/Z-phenylselenovinyl estradiols. Steroids 1998, 63, 479-483.
29. Hanson, R. N.; Napolitano, E.; Fiaschi, R. Synthesis and evaluation of 11β-substituted-21-chloro/iodo-(17α,20E/Z)-19-norpregna-1, 3,5(10),20-tetraene-3,17β-diols: High affinity ligands for the estrogen receptor. J. Med. Chem. 1998, 41, 4686-4692.
30. Gantchev, T. G.; Ali, H.; van Lier, J. E. Quantitative structure activity relationships/comparative molecular field analysis (QSAR/CoMFA) for receptor-binding properties of halognated estradiol derivatives. J. Med. Chem. 1994, 37, 4164-4176.
31. Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. The estradiol pharmacophore: Ligand structure - estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997, 62, 268-303.
32. Gao, H.; Katzenellenbogen, J. A.; Garg, R.; Hansch, C. Comparative QSAR analysis of estrogen receptor ligands. Chem. Rev. 1999, 99, 723-744.
33. Gustafsson, J. A. Estrogen receptor beta - a new dimension in estrogen mechanism of action. J. Endocrinol. 1999, 163, 379-383.
34. Saunders, P. T. Oestrogen receptor beta (ER beta). Rev. Reprod. 1998, 3, 164-171.
35. Barkem, T.; Carlsson, B.; Nilsson, Y.; Enmark, E.; Gustafsson, J. A.; Nilsson, S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
36. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem., Int. Ed. Engl. 1986, 25, 508-524.
37. Farina, V.; Krishnamurthy, V.; Scott, W. J. The Stille reaction. Org. React. 1995, 50, 1-651.
38. Lee, C. Y.; Hanson, R. N. Solid phase synthesis of 17α-E/Z-(Xphenyl)vinyl estradiols using the Stille coupling reaction. Tetrahedron 2000, 56, 1623-1629.
39. Sebag, A. B.; Friel, C. J.; Hanson, R. N.; Forsyth, D. A. Conformational studies on (17α,20Z)-21-(X-phenyl)-19-norpregna-1,3,5(10),20-tetraene-3, 17β-diols using 1D- and 2D-NMR spectroscopy and GIAO calculations from c-13 shieldings. J. Org. Chem. 2000, 65, 7902-7912.
40. Sebag, A. B.; Hanson, R. N.; Forsyth, D. A.; Lee, C. Y. Conformational studies of novel estrogen receptor ligands by 1D and 2D NMR spectroscopy and computational methods. Magn. Reson. Chem. 2003, 41, 246-252.
41. Counsell, R. E.; Klimstra, P. D.; Elton, R. L.; Nutting, E. F. Chemical and biological properties of some 17-substituted estradiol derivatives. J. Med. Chem. 1966, 9, 689-692.
42. Suzuki, A. Synthetic studies via the cross-coupling reaction of organoboron derivatives with organic halides. Pure Appl. Chem. 1991, 63, 419-422.
43. Suzuki, A. Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995-1998. J. Organomet. Chem. 1999, 576, 147-168.
44. Wurtz, J.-M.; Egner, U.; Heinrich, N.; Moras, D.; Mueller-Fahrnow, A. Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationships. J. Med. Chem. 1998, 41, 1803-1814.
45. Sippl, W. Receptor-based 3-D QSAR analysis of estrogen receptor ligands-merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J. Comput.-Aided Mol. Des. 2000, 14, 559-572.
46. Egner, U.; Heinrich, N.; Ruff, M.; Gangloff, M.; Mueller-Fahrnow, A.; Wurtz, J.-M. Different ligands - different receptor conformations: modeling of the hERα-LBD in complexes with agonists and antagonists. Med. Res. Rev. 2001, 21, 523-539.
47. Insight II, 97.2/Discover 2.9.7; MSI Inc.: San Diego, CA., 199_.
48. Marhefka, C. A.; Moore, B. K.; Bishop, T. C.; Kirkovsky, L.; Mukherjee, A.; Dalton, J. T.; Miller, D. D. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 2001, 44, 1729-1740.
49. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, G. Y.; Scheffler, J. E.; Salvati, M. E.; Krystek, S. R., Jr.; Weinmann, R.; Einspahr, H. M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4904-4909.
50. Yamamoto, K.; Masuno, H.; Choi, M.; Nakashime, K.; Taga, T.; Ooizumi, H.; Umesono, K.; Sicinska, W.; VanHooke, J.; DeLuca, H. F.; Yamada, S. Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1467-1472.
51. Suhara, Y.; Nihei, K.-i.; Kurihara, M.; Kittaka, A.; Yamaguchi, K.; Fujishima, T.; Konno, K.; Miyata, N.; Takayama, H. Efficient and versatile synthesis of novel 2α-substituted 1α,25-dihydroxyvitamin D-3 analogues and their docking to vitamin D receptors. J. Org. Chem. 2001, 66, 8760-8771.
52. Tocchini-Valentini, G.; Rochel, N.; Wurtz, J. M.; Mitschler, A.; Moras, D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5491-5496.
53. Nozaki, K.; Oshima, K.; Utimoto, K. EtB3 induced radical addition of Ph3SnH to acetylenes and its application to cyclization reaction. Tetrahedron 1989, 45, 923-933.
54. Palmisano, G.; Santagostino, M. Base-modified pyrimidine nucleosides. Efficient entry to 6-derivatized uridines by Sn-Pd transmetallation-coupling process. Tetrahedron 1993, 49, 2059-2068.
55. Nair, A. C.; Miertus, S.; Tossi, A.; Romeo, D. A computational study of the resistance of HIV-1 aspartic protease to inhibitors ABT-538 and VX-478 and design of new analogues. Biochem. Biophys. Res. Commun. 1998, 242, 545-551.
56. DeLisle, R. K.; Yu, S.-J.; Nair, A. C.; Welsh, W. J. Homology modeling of the estrogen receptor subtype β (ER-β) and calculation of ligand binding affinities. J. Mol. Graphics Modell. 2001, 20, 155-167.
57. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138, 863-870.
58. Sielstad, D. A.; Carlson, K. E.; Katzenellenbogen, J. A.; Kushner, P. J.; Greene, G. L. Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. Mol. Endocrinol. 1993, 9, 647-658.